Floatz logo

Enadenotucirev

Epithelial Tumor

Akamis Bioother_biologicalPhase 1/2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
81/ 100

Competitive context

25 Active assets in the Epithelial Tumor cohort.

Asset / SponsorPhaseRating
Sorafenib
Shandong Cancer Hospital and Institute
Phase 3BB
Catumaxomab
Neovii Biotech
Phase 2/3B
Pembrolizumab
Sheba Medical Center
Phase 2B
Linifanib
Abbott
Phase 3B
Ixabepilone
Cedars-Sinai Medical Center
Phase 2CCC

View all 36 →

Same molecule, other indications

Enadenotucirev is also rated in:

urinary bladder cancerDormant
CCC
Indicative ·
52 / 100
View asset →
ovarian cancerDormant
CC
Indicative ·
47 / 100
View asset →
head and neck squamous cell carcinomaDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →